The Company intends to advance the patent process in certain European countries in line with TCBP’s business strategy.
“We are excited to further expand our patent portfolio at TCBP with this European patent for modified gamma delta T cells,” said Bryan Kobel, CEO of TC BioPharm. “TCBP remains focused on our immediate applications for TCB008 while developing future high-value gamma delta assets for other indications such as solid tumors. We believe that modified gamma deltas can be a powerful therapeutic with the potential to outperform current CAR and modified T cells in terms of safety and efficacy. Patent protection of these approaches provides us with a competitive advantage and further value in a potential acquisition scenario.”
Forward-looking statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical fact included in this Current Report on Form 8-K should be considered forward-looking statements, including, without limitation, statements regarding the Company’s intention or ability to achieve budget savings or to implement M&A or capital raising strategies. These statements are based on management’s current assumptions and are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause the Company’s actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. For additional important factors that could cause actual results to differ materially from the forward-looking statements in this Current Report on Form 8-K, see the risks and uncertainties listed under the heading “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2023 and our other reports filed with the SEC, all of which are available on the Company’s Investor Relations website at www.tcbiopharm.com and on the SEC website at www.sec.gov. All forward-looking statements reflect the Company’s beliefs and assumptions only as of the date of this press release. The Company undertakes no obligation to update any forward-looking statements to reflect future events or circumstances.
About TC BioPharm (Holdings) PLC
TC BioPharm is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing gamma delta T cell therapies to treat cancer with in-human efficacy data in acute myeloid leukemia. Gamma delta T cells are naturally occurring immune cells that embody properties of both the innate and adaptive immune systems and have the inherent ability to distinguish between healthy and diseased tissue. TC BioPharm is a leader in the development of gamma delta T cell therapies and the first company to conduct Phase II/pivotal clinical trials in oncology. The Company is conducting two investigator-initiated clinical trials for its unmodified gamma delta T cell product line – a Phase 2b/3 pivotal trial for the treatment of acute myeloid leukemia using the Company’s proprietary allogeneic CryoTC technology to provide frozen products to clinics worldwide.
View original content to download multimedia: https://www.prnewswire.com/news-releases/tc-biopharm-announces-grant-of-european-patent-covering-use-of-modified-gamma-delta-cells-for-the-treatment-of-cancer-and-viral-indications-302233266.html
Don’t miss any more stories from TC BioPharm.
